XPR – Lifestyle Demo
Author:
Beam Therapeutics
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 12, 2026
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 7, 2026
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
April 1, 2026
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026